StockData
Aptevo Therapeutics Inc. logo

Aptevo Therapeutics Inc. (APVO) stock

APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.46−0.09 (-15.97%)

Close on Nov 17, 2026Market cap $830.71KP/E –Yield –

Aptevo Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Aptevo Therapeutics's total debt was $3.46M at Dec 31, 2022. For fiscal 2022 it was $3.46M, down 77.5% from the year before. The highest annual figure on record is $19.86M in fiscal 2019.

Annual total debt

PeriodPeriod endValueChange
FY2022Dec 31, 2022$3.46M-77.5%
FY2021Dec 31, 2021$15.37M+207.5%
FY2020Dec 31, 2020$5.00M-74.8%
FY2019Dec 31, 2019$19.86M+3.0%
FY2018Dec 31, 2018$19.28M+1.1%
FY2017Dec 31, 2017$19.06M+3.7%
FY2016Dec 31, 2016$18.38M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022$3.46M-77.5%
Q3 FY2022Sep 30, 2022$3.91M-65.0%
Q2 FY2022Jun 30, 2022$2.00M-81.3%
Q1 FY2022Mar 31, 2022$2.00M-80.3%
Q4 FY2021Dec 31, 2021$15.37M+207.5%
Q3 FY2021Sep 30, 2021$11.17M-43.8%
Q2 FY2021Jun 30, 2021$10.67M-45.5%
Q1 FY2021Mar 31, 2021$10.17M-47.6%
Q4 FY2020Dec 31, 2020$5.00M-74.1%
Q4 FY2019Dec 31, 2019$19.86M+3.8%
Q2 FY2019Jun 30, 2019$19.56M-0.0%
Q1 FY2019Mar 31, 2019$19.42M+0.6%
Q4 FY2018Dec 31, 2018$19.28M+1.1%
Q3 FY2018Sep 30, 2018$19.14M+9.5%
Q2 FY2018Jun 30, 2018$19.57M+4.4%
Q1 FY2018Mar 31, 2018$19.31M+4.7%
Q4 FY2017Dec 31, 2017$19.06M+3.7%
Q3 FY2017Sep 30, 2017$17.48M-3.5%
Q2 FY2017Jun 30, 2017$18.75M–
Q1 FY2017Mar 31, 2017$18.44M–
Q4 FY2016Dec 31, 2016$18.38M–
Q3 FY2016Sep 30, 2016$18.11M–

More Aptevo Therapeutics figures

See a number that looks wrong?